These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21726192)

  • 1. Receptor-based pharmacophore and pharmacophore key descriptors for virtual screening and QSAR modeling.
    Dong X; Ebalunode JO; Yang SY; Zheng W
    Curr Comput Aided Drug Des; 2011 Sep; 7(3):181-9. PubMed ID: 21726192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the value of homology models for virtual screening: discovering hCXCR3 antagonists by pharmacophore-based and structure-based approaches.
    Huang D; Gu Q; Ge H; Ye J; Salam NK; Hagler A; Chen H; Xu J
    J Chem Inf Model; 2012 May; 52(5):1356-66. PubMed ID: 22545675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore based drug design approach as a practical process in drug discovery.
    Gao Q; Yang L; Zhu Y
    Curr Comput Aided Drug Des; 2010 Mar; 6(1):37-49. PubMed ID: 20370694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New features that improve the pharmacophore tools from Accelrys.
    Sutter J; Li J; Maynard AJ; Goupil A; Luu T; Nadassy K
    Curr Comput Aided Drug Des; 2011 Sep; 7(3):173-80. PubMed ID: 21726193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening.
    Tanrikulu Y; Schneider G
    Nat Rev Drug Discov; 2008 Aug; 7(8):667-77. PubMed ID: 18636071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From activity cliffs to target-specific scoring models and pharmacophore hypotheses.
    Seebeck B; Wagener M; Rarey M
    ChemMedChem; 2011 Sep; 6(9):1630-9, 1533. PubMed ID: 21751401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular shape technologies in drug discovery: methods and applications.
    Ebalunode JO; Zheng W
    Curr Top Med Chem; 2010; 10(6):669-79. PubMed ID: 20337591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs.
    Fan F; Toledo Warshaviak D; Hamadeh HK; Dunn RT
    PLoS One; 2019; 14(1):e0204378. PubMed ID: 30605479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening.
    Pérez-Nueno VI; Pettersson S; Ritchie DW; Borrell JI; Teixidó J
    J Chem Inf Model; 2009 Apr; 49(4):810-23. PubMed ID: 19358515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-based virtual screening.
    Horvath D
    Methods Mol Biol; 2011; 672():261-98. PubMed ID: 20838973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting de novo drug design: receptor based pharmacophore screening.
    Amaravadhi H; Baek K; Yoon HS
    Curr Top Med Chem; 2014; 14(16):1890-8. PubMed ID: 25262804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore modeling and applications in drug discovery: challenges and recent advances.
    Yang SY
    Drug Discov Today; 2010 Jun; 15(11-12):444-50. PubMed ID: 20362693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore-Map-Pick: A Method to Generate Pharmacophore Models for All Human GPCRs.
    Dai SX; Li GH; Gao YD; Huang JF
    Mol Inform; 2016 Feb; 35(2):81-91. PubMed ID: 27491793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.
    Aboalhaija NH; Zihlif MA; Taha MO
    Chem Biol Interact; 2016 Apr; 250():12-26. PubMed ID: 26954606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of QSAR and shape pharmacophore modeling approaches for targeted chemical library design.
    Ebalunode JO; Zheng W; Tropsha A
    Methods Mol Biol; 2011; 685():111-33. PubMed ID: 20981521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel VP35 inhibitors: Virtual screening driven new scaffolds.
    Ren JX; Zhang RT; Zhang H; Cao XS; Liu LK; Xie Y
    Biomed Pharmacother; 2016 Dec; 84():199-207. PubMed ID: 27657828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
    Taha MO; Atallah N; Al-Bakri AG; Paradis-Bleau C; Zalloum H; Younis KS; Levesque RC
    Bioorg Med Chem; 2008 Feb; 16(3):1218-35. PubMed ID: 17988876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative structure activity relationship and pharmacophore studies of adenosine receptor A2B inhibitors.
    Joseph TB; Suneel Kumar BV; Santhosh B; Kriti S; Pramod AB; Ravikumar M; Kishore M
    Chem Biol Drug Des; 2008 Nov; 72(5):395-408. PubMed ID: 19012575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
    Chaudhari P; Bari S
    Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-D and 3-D modeling of imidazoline receptor ligands: insights into pharmacophore.
    Carrieri A; Brasili L; Leonetti F; Pigini M; Giannella M; Bousquet P; Carotti A
    Bioorg Med Chem; 1997 May; 5(5):843-56. PubMed ID: 9208096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.